Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Sales (2021 - 2024)

Allogene Therapeutics (ALLO) has disclosed Return on Sales for 4 consecutive years, with 11510.32% as the latest value for Q4 2024.

  • Quarterly Return on Sales fell 775584.0% to 11510.32% in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 11510.32% through Dec 2024, down 825316.0% year-over-year, with the annual reading at 11708.64% for FY2024, 826374.0% down from the prior year.
  • Return on Sales hit 11510.32% in Q4 2024 for Allogene Therapeutics, down from 6384.35% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.03% in Q4 2021 to a low of 11510.32% in Q4 2024.
  • Historically, Return on Sales has averaged 3186.92% across 4 years, with a median of 2965.59% in 2022.
  • Biggest five-year swings in Return on Sales: surged 43744bps in 2023 and later tumbled -775584bps in 2024.
  • Year by year, Return on Sales stood at 0.03% in 2021, then crashed by -14392819bps to 3601.46% in 2022, then fell by -4bps to 3754.48% in 2023, then crashed by -207bps to 11510.32% in 2024.
  • Business Quant data shows Return on Sales for ALLO at 11510.32% in Q4 2024, 6384.35% in Q3 2024, and 4094.6% in Q2 2024.